5-HT1B receptor

{{Short description|Mammalian protein found in Homo sapiens}} {{DISPLAYTITLE:5-HT1B receptor}} {{cs1 config|name-list-style=vanc|display-authors=6}} {{Infobox gene}}

'''5-hydroxytryptamine receptor 1B''' also known as the '''5-HT1B receptor''' is a protein that in humans is encoded by the ''HTR1B'' gene.<ref name="pmid1348246">{{cite journal | vauthors = Jin H, Oksenberg D, Ashkenazi A, Peroutka SJ, Duncan AM, Rozmahel R, Yang Y, Mengod G, Palacios JM, O'Dowd BF | title = Characterization of the human 5-hydroxytryptamine1B receptor | journal = The Journal of Biological Chemistry | volume = 267 | issue = 9 | pages = 5735–8 | date = Mar 1992 | doi = 10.1016/S0021-9258(18)42612-9 | pmid = 1348246 | doi-access = free }}</ref><ref name="pmid11247661">{{cite journal | vauthors = Sanders AR, Cao Q, Taylor J, Levin TE, Badner JA, Cravchik A, Comeron JM, Naruya S, Del Rosario A, Salvi DA, Walczyk KA, Mowry BJ, Levinson DF, Crowe RR, Silverman JM, Gejman PV | title = Genetic diversity of the human serotonin receptor 1B (HTR1B) gene | journal = Genomics | volume = 72 | issue = 1 | pages = 1–14 | date = Feb 2001 | pmid = 11247661 | doi = 10.1006/geno.2000.6411 }}</ref> The 5-HT1B receptor is a 5-HT receptor subtype.<ref name="entrez">{{cite web | title = Entrez Gene: HTR1B 5-hydroxytryptamine (serotonin) receptor 1B| url = https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=3351}}</ref>

==Tissue distribution and function== 5-HT1B receptors are widely distributed throughout the central nervous system with the highest concentrations found in the frontal cortex, basal ganglia, striatum, and the hippocampus.<ref>{{cite web | title = 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled| url = https://www.genecards.org/cgi-bin/carddisp.pl?gene=HTR1B| access-date = 23 Feb 2013}}</ref> The function of the 5-HT1B receptor differs depending upon its location. In the frontal cortex, it is believed to act as a terminal receptor inhibiting the release of dopamine. In the basal ganglia and the striatum, evidence suggests 5-HT signaling acts on an autoreceptor, inhibiting the release of serotonin<ref>{{cite journal | vauthors = Pytliak M, Vargová V, Mechírová V, Felšöci M | title = Serotonin receptors - from molecular biology to clinical applications | journal = Physiological Research | volume = 60 | issue = 1 | pages = 15–25 | year = 2011 | pmid = 20945968 | doi = 10.33549/physiolres.931903 | doi-access = free }}</ref> and decreasing glutamatergic transmission by reducing miniature excitatory postsynaptic potential (mEPSP) frequency,<ref name="pmid23452061">{{cite journal | vauthors = Huang CC, Yeh CM, Wu MY, Hsu KS | title = A single in vivo cocaine administration impairs 5-HT(1B) receptor-induced long-term depression in the nucleus accumbens | journal = Journal of Neurochemistry | volume = 125 | issue = 6 | pages = 809–21 | date = Jun 2013 | pmid = 23452061 | doi = 10.1111/jnc.12227 | s2cid = 45859780 | doi-access = free }}</ref> respectively. In the hippocampus, a recent study has demonstrated that activation of postsynaptic 5-HT1B heteroreceptors produces a facilitation in excitatory synaptic transmission which is altered in depression.<ref name="pmid23502536">{{cite journal | vauthors = Cai X, Kallarackal AJ, Kvarta MD, Goluskin S, Gaylor K, Bailey AM, Lee HK, Huganir RL, Thompson SM | title = Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression | journal = Nature Neuroscience | volume = 16 | issue = 4 | pages = 464–72 | date = Apr 2013 | pmid = 23502536 | doi = 10.1038/nn.3355 | pmc=3609911}}</ref> When the expression of 5-HT1B in human cortex was traced throughout life, significant changes during adolescence were observed, in a way that is strongly correlated with the expression of 5-HT1E.<ref name="pmid24721318">{{cite journal | vauthors = Shoval G, Bar-Shira O, Zalsman G, John Mann J, Chechik G | title = Transitions in the transcriptome of the serotonergic and dopaminergic systems in the human brain during adolescence | journal = European Neuropsychopharmacology | volume = 24 | issue = 7 | pages = 1123–32 | date = Jul 2014 | pmid = 24721318 | doi = 10.1016/j.euroneuro.2014.02.009 | s2cid = 14534307 }}</ref>

Outside of the CNS, the 5-HT1B receptor is also expressed on the endothelium of blood vessels, particularly in the meninges.<ref name="Tepper">{{cite journal | vauthors = Tepper SJ, Rapoport AM, Sheftell FD | title = Mechanisms of action of the 5-HT1B/1D receptor agonists | journal = Archives of Neurology | volume = 59 | issue = 7 | pages = 1084–1088 | date = July 2002 | pmid = 12117355 | doi = 10.1001/archneur.59.7.1084 | doi-access = free }}</ref> Activation of these receptors results in vasoconstriction. The high distribution of vasoconstrictive 5-HT1B and 5-HT1D receptors around the brain makes them a valuable drug target for the treatment of migraines.<ref name="Tepper" />

Blocking 5-HT1B receptor signalling also increases the number of osteoblasts, bone mass, and the bone formation rate.<ref name="pmid19041748">{{cite journal | vauthors = Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G | title = Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum | journal = Cell | volume = 135 | issue = 5 | pages = 825–37 | date = Nov 2008 | pmid = 19041748 | pmc = 2614332 | doi = 10.1016/j.cell.2008.09.059}} *{{lay source|template=cite web |author=Michael Smith |title=Serotonin in Gut Linked to Bone Formation |url=http://www.medpagetoday.com/Endocrinology/Osteoporosis/11923 |website=Medpage Today |archive-url=https://web.archive.org/web/20160303214730/http://www.medpagetoday.com/Endocrinology/Osteoporosis/11923 |archive-date=2016-03-03}}</ref>

Knockout mice lacking the 5-HT1B gene have been reported to have a higher preference for alcohol, although later studies failed to replicate such abnormalities in alcohol consumption.<ref name="pmid11888546">{{cite journal | vauthors = Hoyer D, Hannon JP, Martin GR | title = Molecular, pharmacological and functional diversity of 5-HT receptors | journal = Pharmacology Biochemistry and Behavior | volume = 71 | issue = 4 | pages = 533–54 | date = Apr 2002 | pmid = 11888546 | doi = 10.1016/S0091-3057(01)00746-8 | s2cid = 25543069 }}</ref> These mice have also been reported to have a lower measure of anxiety (such as on the elevated plus maze test) and a higher measure of aggression.<ref name="pmid11888546" />

Under basal conditions, knockout mice present with a "normal" phenotype and exhibit a sucrose preference (lack of sucrose preference is considered a measure of anhedonia). However, after undergoing chronic unpredictable stress treatment to induce a "depression-like" phenotype these animals do not benefit from administration of selective serotonin reuptake inhibitor (SSRIs).<ref name="pmid23502536" />{{Failed verification|date=September 2020}}

Activation of the serotonin 5-HT1B receptor appears to mediate the prosocial effects of entactogens acting as serotonin releasing agents like MDMA in animals.<ref name="Nichols2022">{{cite journal | vauthors = Nichols DE | title = Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated | journal = Front Psychiatry | volume = 13 | issue = | article-number = 863088 | date = 2022 | pmid = 35401275 | pmc = 8990025 | doi = 10.3389/fpsyt.2022.863088 | doi-access = free | url = }}</ref><ref name="ReinRaymondBoustani2024">{{cite journal | vauthors = Rein B, Raymond K, Boustani C, Tuy S, Zhang J, St Laurent R, Pomrenze MB, Boroon P, Heifets B, Smith M, Malenka RC | title = MDMA enhances empathy-like behaviors in mice via 5-HT release in the nucleus accumbens | journal = Sci Adv | volume = 10 | issue = 17 | article-number = eadl6554 | date = April 2024 | pmid = 38657057 | pmc = 11042730 | doi = 10.1126/sciadv.adl6554 | bibcode = 2024SciA...10L6554R | url = }}</ref><ref name="HeifetsSalgadoTaylor2019">{{cite journal | vauthors = Heifets BD, Salgado JS, Taylor MD, Hoerbelt P, Cardozo Pinto DF, Steinberg EE, Walsh JJ, Sze JY, Malenka RC | title = Distinct neural mechanisms for the prosocial and rewarding properties of MDMA | journal = Sci Transl Med | volume = 11 | issue = 522 | pages = | date = December 2019 | pmid = 31826983 | pmc = 7123941 | doi = 10.1126/scitranslmed.aaw6435 | url = }}</ref><ref name="WalshLlorachCardozoPinto2021">{{cite journal | vauthors = Walsh JJ, Llorach P, Cardozo Pinto DF, Wenderski W, Christoffel DJ, Salgado JS, Heifets BD, Crabtree GR, Malenka RC | title = Systemic enhancement of serotonin signaling reverses social deficits in multiple mouse models for ASD | journal = Neuropsychopharmacology | volume = 46 | issue = 11 | pages = 2000–2010 | date = October 2021 | pmid = 34239048 | pmc = 8429585 | doi = 10.1038/s41386-021-01091-6 | url = }}</ref> In addition, serotonin 5-HT1B receptor activation appears to mediate the locomotor hyperactivity of these agents.<ref name="Martinez-PriceKrebs-ThomsonGeyer2002">{{cite journal | vauthors = Martinez-Price D, Krebs-Thomson K, Geyer M | title=Behavioral Psychopharmacology of MDMA and MDMA-Like Drugs: A Review of Human and Animal Studies | journal=Addiction Research & Theory | publisher=Informa UK Limited | volume=10 | issue=1 | date=1 January 2002 | issn=1606-6359 | doi=10.1080/16066350290001704 | pages=43–67}}</ref><ref name="RempelCallawayGeyer1993">{{cite journal | vauthors = Rempel NL, Callaway CW, Geyer MA | title = Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release | journal = Neuropsychopharmacology | volume = 8 | issue = 3 | pages = 201–211 | date = May 1993 | pmid = 8099482 | doi = 10.1038/npp.1993.22 | url = }}</ref><ref name="Scearce-LevieViswanathanHen1999">{{cite journal | vauthors = Scearce-Levie K, Viswanathan SS, Hen R | title = Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor | journal = Psychopharmacology | location = Berlin | volume = 141 | issue = 2 | pages = 154–161 | date = January 1999 | pmid = 9952039 | doi = 10.1007/s002130050819 }}</ref> The serotonin 5-HT1B receptor also appears to be required for the persisting antidepressant- and anxiolytic-like effects as well as acute hypolocomotion of the serotonergic psychedelic and non-selective serotonin receptor agonist psilocybin in animals.<ref name="FleuryNautiyal2024">{{cite journal | vauthors = Fleury S, Nautiyal K | title = ACNP 63rd Annual Meeting: Poster Abstracts P609-P914: P691. The Non-Hallucinogenic Serotonin 1B Receptor is Necessary for the Persisting Behavioral Effects of Psilocybin in Mice | journal = Neuropsychopharmacology | volume = 49 | issue = Suppl 1 | pages = 418–594 (466) | date = December 2024 | pmid = 39643635 | doi = 10.1038/s41386-024-02013-y | url = | doi-access = free }}</ref>

==Ligands==

===Agonists=== {{Div col|colwidth=20em}} * 2ZEDMA (also a 5-HT2A agonist) * 5-Carboxamidotryptamine (5-CT) * 5-MAPB<ref name="US20230150963">{{cite patent | country = US | number = 20230150963 | inventor = Matthew Baggott | status = | title = Advantageous benzofuran compositions for mental disorders or enhancement | pubdate = 2023 May 18 | gdate = | fdate = 2022 December 8 | pridate = 2022 December 8 | assign1 = Tactogen | url = https://patents.google.com/patent/US20230150963A1/en}}</ref> * 5-MAPBT<ref name="WO2022010937">{{cite patent | url = https://patents.google.com/patent/WO2022010937A1 | inventor = Baggott M | assign = Tactogen Inc. | pubdate = 13 January 2022 | title = Advantageous benzothiophene compositions for mental disorders or enhancement. | country = WO | number = 2022/010937 }}</ref> * 6-MAPB<ref name="US20230150963" /> * 6-MAPBT<ref name="WO2022010937" /> * Almotriptan * Anpirtoline (D-16949) * Avitriptan * Batoprazine * BK-5-MAPB<ref name="US20230150963" /> * BK-5-MAPBT<ref name="WO2022010937" /> * BK-6-MAPB<ref name="US20230150963" /> * CGS-12066 (CGS-12066A, CGS-12066B) * CP-93,129 * CP-94,253 * CP-122,288 (mixed 5-HT1B/1D agonist) * CP-135,807 (mixed 5-HT1B/1D agonist) * Dihydroergotamine * Donitriptan * Eletriptan * Eltoprazine (DU-28853) * Emodin-8-glucoside * Ergotamine * Fluprazine * Frovatriptan * L-741604 * Lisuride * mCPP * MDMA<ref name="JainGumpperSlocum2025">{{cite journal | vauthors = Jain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, Suomivuori CM, Huang XP, Shub L, DiBerto JF, Kim K, DeLeon C, Krumm BE, Fay JF, Keiser M, Hauser AS, Dror RO, Shoichet B, Gloriam DE, Nichols DE, Roth BL | title = The polypharmacology of psychedelics reveals multiple targets for potential therapeutics | journal = Neuron | date = July 2025 | volume = 113 | issue = 19 | pages = 3129–3142.e9 | pmid = 40683247 | doi = 10.1016/j.neuron.2025.06.012 | url = https://www.cell.com/cms/10.1016/j.neuron.2025.06.012/attachment/7d8365fe-51f3-4a28-bf40-9999bec837f6/mmc11.pdf }}</ref> * Methylergometrine (methylergonovine) * Methylone<ref name="JainGumpperSlocum2025" /> * Methysergide * Naratriptan * Oxymetazoline * Pergolide * PGI-7043 * PZKKN-94 (also a 5-HT6 antagonist)<ref name="ZajdelMatłokaKonieczny2025">{{cite journal | vauthors = Zajdel P, Matłoka M, Konieczny J, Kos T, Lammers JC, Cavalco NG, Clark AA, Lenda T, Satała G, Canale V, Grychowska K, Krawczyk M, Nikiforuk A, Partyka A, Jastrzębska-Więsek M, Berghauzen-Maciejewska K, Biała D, Janicka M, Janusz A, Piast R, Mulewski K, Smuga D, Pieczykolan J, Wieczorek M, Moszczyński-Pętkowski R, Dubiel K, Ossowska K, Bojarski AJ, Kamiński K, McCorvy JD, Popik P | title = Simultaneous 5-HT1BR agonist/5-HT6R antagonist action as a potential treatment of Parkinson's disease and its comorbidities | journal = J Pharmacol Exp Ther | volume = 392 | issue = 2 | article-number = 100055 | date = February 2025 | pmid = 40023605 | doi = 10.1016/j.jpet.2024.100055 | url = | doi-access = free }}</ref> * Rizatriptan * RU-24969 (mixed 5-HT1A/1B agonist) * (S)-DCPT * Serotonin * Sumatriptan * TFMPP * Tryptamine psychedelics (e.g., 5-MeO-DMT, DPT, psilocin/psilocybin) * Zolmitriptan {{Div col end}}

===Partial agonists=== {{Div col|colwidth=20em}} * Asenapine * AZ10419369 * Bromocriptine * Metergoline * Naphthylpiperazine * Vortioxetine * Ziprasidone {{Div col end}}

===Antagonists and inverse agonists=== {{Div col|colwidth=20em}} * Alprenolol * AOP-208 (LB-208) * AR-A000002 (AZD-8129)<ref>{{cite journal | vauthors = Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M, Ryan C, Ross S, Stenfors C | title = Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 304 | issue = 3 | pages = 1072–84 | date = Mar 2003 | pmid = 12604684 | doi = 10.1124/jpet.102.045468 | s2cid = 20463714 }}</ref> * Aripiprazole * AZD-1134 * AZD-3783 * AZ12320927 * Carteolol * Elzasonan * F-14258 * GR-55562 * GR-127935 * Isamoltane (CGP-361A) * LY-393558 * Metitepine (methiothepin) * NAS-181 (MCOMM) * Oxprenolol * Penbutolol * Propranolol * Risperidone * SB-216,641 * SB-224,289 (inverse agonist)<ref>{{cite journal | vauthors = Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, Collin L, Jones BJ, Middlemiss DN, Price GW | title = SB-224289--a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity | journal = British Journal of Pharmacology | volume = 125 | issue = 1 | pages = 202–8 | date = Sep 1998 | pmid = 9776361 | pmc = 1565605 | doi = 10.1038/sj.bjp.0702059 }}</ref> * SB-236,057 (inverse agonist)<ref>{{cite journal | vauthors = Roberts C, Watson J, Price GW, Middlemiss DN | title = SB-236057-A: a selective 5-HT1B receptor inverse agonist | journal = CNS Drug Reviews | volume = 7 | issue = 4 | pages = 433–44 | year = 2001 | pmid = 11830759 | doi = 10.1111/j.1527-3458.2001.tb00209.x | pmc = 6741665 }}</ref> * SB-245,570 * SB-616234 * SB-649,915 * Tertatolol * Yohimbine {{Div col end}}

===Negative allosteric modulators=== * 5-HT-moduline

===Unknown=== * Dextromethorphan<ref>{{Cite journal|vauthors=Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR|year=2016|title=Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders|journal=Pharmacol. Ther.|volume=159|pages=1–22|pmid=26826604|doi=10.1016/j.pharmthera.2016.01.016|doi-access=free}}</ref>

== Genetics == In humans the protein is coded by the gene ''HTR1B''.

A genetic variant in the promoter region, ''A-161T'', has been examined with respect to personality traits and showed no major effect.<ref name="pmid14504413">{{cite journal | vauthors = Tsai SJ, Wang YC, Chen JY, Hong CJ | title = Allelic variants of the tryptophan hydroxylase (A218C) and serotonin 1B receptor (A-161T) and personality traits | journal = Neuropsychobiology | volume = 48 | issue = 2 | pages = 68–71 | year = 2003 | pmid = 14504413 | doi = 10.1159/000072879 | s2cid = 42559772 }}</ref>

== See also == * 5-HT1 receptor * 5-HT receptor

== References == {{reflist|33em}}

== Further reading == {{refbegin|33em}} * {{cite journal | vauthors = Olivier B, van Oorschot R | title = 5-HT1B receptors and aggression: a review | journal = European Journal of Pharmacology | volume = 526 | issue = 1–3 | pages = 207–17 | date = Dec 2005 | pmid = 16310769 | doi = 10.1016/j.ejphar.2005.09.066 }} * {{cite journal | vauthors = Hamblin MW, Metcalf MA, McGuffin RW, Karpells S | title = Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity | journal = Biochemical and Biophysical Research Communications | volume = 184 | issue = 2 | pages = 752–9 | date = Apr 1992 | pmid = 1315531 | doi = 10.1016/0006-291X(92)90654-4 }} * {{cite journal | vauthors = Veldman SA, Bienkowski MJ | title = Cloning and pharmacological characterization of a novel human 5-hydroxytryptamine1D receptor subtype | journal = Molecular Pharmacology | volume = 42 | issue = 3 | pages = 439–44 | date = Sep 1992 | pmid = 1328844 }} * {{cite journal | vauthors = Demchyshyn L, Sunahara RK, Miller K, Teitler M, Hoffman BJ, Kennedy JL, Seeman P, Van Tol HH, Niznik HB | title = A human serotonin 1D receptor variant (5HT1D beta) encoded by an intronless gene on chromosome 6 | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 89 | issue = 12 | pages = 5522–6 | date = Jun 1992 | pmid = 1351684 | pmc = 49324 | doi = 10.1073/pnas.89.12.5522 | bibcode = 1992PNAS...89.5522D | doi-access = free }} * {{cite journal | vauthors = Levy FO, Gudermann T, Perez-Reyes E, Birnbaumer M, Kaumann AJ, Birnbaumer L | title = Molecular cloning of a human serotonin receptor (S12) with a pharmacological profile resembling that of the 5-HT1D subtype | journal = The Journal of Biological Chemistry | volume = 267 | issue = 11 | pages = 7553–62 | date = Apr 1992 | doi = 10.1016/S0021-9258(18)42552-5 | pmid = 1559993 | doi-access = free }} * {{cite journal | vauthors = Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA, Hartig PR | title = Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 89 | issue = 8 | pages = 3630–4 | date = Apr 1992 | pmid = 1565658 | pmc = 48922 | doi = 10.1073/pnas.89.8.3630 | bibcode = 1992PNAS...89.3630W | doi-access = free }} * {{cite journal | vauthors = Mochizuki D, Yuyama Y, Tsujita R, Komaki H, Sagai H | title = Cloning and expression of the human 5-HT1B-type receptor gene | journal = Biochemical and Biophysical Research Communications | volume = 185 | issue = 2 | pages = 517–23 | date = Jun 1992 | pmid = 1610347 | doi = 10.1016/0006-291X(92)91655-A }} * {{cite journal | vauthors = Nöthen MM, Erdmann J, Shimron-Abarbanell D, Propping P | title = Identification of genetic variation in the human serotonin 1D beta receptor gene | journal = Biochemical and Biophysical Research Communications | volume = 205 | issue = 2 | pages = 1194–200 | date = Dec 1994 | pmid = 7802650 | doi = 10.1006/bbrc.1994.2792 }} * {{cite journal | vauthors = Ng GY, George SR, Zastawny RL, Caron M, Bouvier M, Dennis M, O'Dowd BF | title = Human serotonin1B receptor expression in Sf9 cells: phosphorylation, palmitoylation, and adenylyl cyclase inhibition | journal = Biochemistry | volume = 32 | issue = 43 | pages = 11727–33 | date = Nov 1993 | pmid = 8218242 | doi = 10.1021/bi00094a032 }} * {{cite journal | vauthors = Bouchelet I, Cohen Z, Case B, Séguéla P, Hamel E | title = Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels | journal = Molecular Pharmacology | volume = 50 | issue = 2 | pages = 219–23 | date = Aug 1996 | pmid = 8700126 }} * {{cite journal | vauthors = Varnäs K, Hall H, Bonaventure P, Sedvall G | title = Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [(3)H]GR 125743 | journal = Brain Research | volume = 915 | issue = 1 | pages = 47–57 | date = Oct 2001 | pmid = 11578619 | doi = 10.1016/S0006-8993(01)02823-2 | s2cid = 43104381 }} * {{cite journal | vauthors = Salim K, Fenton T, Bacha J, Urien-Rodriguez H, Bonnert T, Skynner HA, Watts E, Kerby J, Heald A, Beer M, McAllister G, Guest PC | title = Oligomerization of G-protein-coupled receptors shown by selective co-immunoprecipitation | journal = The Journal of Biological Chemistry | volume = 277 | issue = 18 | pages = 15482–5 | date = May 2002 | pmid = 11854302 | doi = 10.1074/jbc.M201539200 | doi-access = free }} * {{cite journal | vauthors = Hasegawa Y, Higuchi S, Matsushita S, Miyaoka H | title = Association of a polymorphism of the serotonin 1B receptor gene and alcohol dependence with inactive aldehyde dehydrogenase-2 | journal = Journal of Neural Transmission | volume = 109 | issue = 4 | pages = 513–21 | date = Apr 2002 | pmid = 11956970 | doi = 10.1007/s007020200042 | s2cid = 35750034 }} * {{cite journal | vauthors = Hawi Z, Dring M, Kirley A, Foley D, Kent L, Craddock N, Asherson P, Curran S, Gould A, Richards S, Lawson D, Pay H, Turic D, Langley K, Owen M, O'Donovan M, Thapar A, Fitzgerald M, Gill M | title = Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi-centre sample | journal = Molecular Psychiatry | volume = 7 | issue = 7 | pages = 718–25 | year = 2003 | pmid = 12192616 | doi = 10.1038/sj.mp.4001048 | doi-access = free }} * {{cite journal | vauthors = Huang YY, Oquendo MA, Friedman JM, Greenhill LL, Brodsky B, Malone KM, Khait V, Mann JJ | title = Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism | journal = Neuropsychopharmacology | volume = 28 | issue = 1 | pages = 163–9 | date = Jan 2003 | pmid = 12496953 | doi = 10.1038/sj.npp.1300000 | doi-access = free }} * {{cite journal | vauthors = Quist JF, Barr CL, Schachar R, Roberts W, Malone M, Tannock R, Basile VS, Beitchman J, Kennedy JL | title = The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder | journal = Molecular Psychiatry | volume = 8 | issue = 1 | pages = 98–102 | date = Jan 2003 | pmid = 12556913 | doi = 10.1038/sj.mp.4001244 | doi-access = free }} * {{cite journal | vauthors = Sinha R, Cloninger CR, Parsian A | title = Linkage disequilibrium and haplotype analysis between serotonin receptor 1B gene variations and subtypes of alcoholism | journal = American Journal of Medical Genetics Part B | volume = 121B | issue = 1 | pages = 83–8 | date = Aug 2003 | pmid = 12898580 | doi = 10.1002/ajmg.b.20064 | s2cid = 33460360 }} {{refend}}

== External links == * {{cite web | url = http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=2 | title = 5-HT1B | work = IUPHAR Database of Receptors and Ion Channels | publisher = International Union of Basic and Clinical Pharmacology }} * {{UCSC gene info|HTR1B}} * {{PDBe-KB2|P28222|5-hydroxytryptamine receptor 1B}}

Category:Serotonin receptors Category:Biology of attention deficit hyperactivity disorder